The Catholic University of Korea, Bucheon St. Mary's Hospital
Welcome,         Profile    Billing    Logout  
 49 Trials 
741 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LEE, Soo Chin
NCT03518957: 12-week Exercise Intervention Program Versus Observation in Early Stage Breast Cancer Patients on the Impact on Mental Health, Quality of Life and Immune Markers

Recruiting
3
304
RoW
Exercise
National University Hospital, Singapore
Breast Cancer
12/21
12/25
KONCLUDE, NCT02843191: Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy

Active, not recruiting
3
358
RoW
Chemotherapy
Kyung Hee University Hospital at Gangdong, Korean Society of ColoProctology, Pharmbio Korea Inc., Samjin Pharmaceutical Co., Ltd., Boryung Pharmaceutical Co., Ltd, JW Pharmaceutical
Rectal Cancer
07/23
06/26
NCT04381689: Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants

Recruiting
3
245
RoW
IL-YANG FLU Vaccine Prefilled Syringe INJ., Fluarix Tetra Pre-filled Syringe
Il-Yang Pharm. Co., Ltd.
Healthy
02/25
06/25
NCT03519074: Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction

Active, not recruiting
2
48
RoW
TS-1 combined with cisplatin
National University Hospital, Singapore
Cancer, Liver Dysfunction
09/24
12/25
AUROR, NCT03989089: Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

Active, not recruiting
2
44
RoW
Pembrolizumab, Keytruda
University of Malaya, Merck Sharp & Dohme LLC, National University Hospital, Singapore, Cancer Research Malaysia
HER2-Negative Breast Cancer
12/25
12/26
NCT04280536: Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)

Recruiting
2
86
RoW
Cohort A, trifluridine/tipiracil, TAS-102 [Lonsurf], Cohort B
National University Hospital, Singapore
Breast Cancer
10/24
10/24
NCT05181033: Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Recruiting
2
120
RoW
Lenvatinib + Letrozole, Lenvima, Fulvestrant, Faslodex
National University Hospital, Singapore, Eisai Co., Ltd.
Breast Cancer
08/25
08/25
NCT06027983: Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

Not yet recruiting
2
36
NA
Chimeric receptor T-cells + Trastuzumab, Fludarabine and Cyclophosphosphamide, Lymphodepletion
National University Hospital, Singapore
HER2+ Advanced Breast Cancer, Other Solid Tumors
12/25
12/27
NCT05035745: Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Recruiting
1/2
63
RoW
Talazoparib, Selinexor
National University Hospital, Singapore
Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast Cancers
11/24
11/25
NCT05381038: Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Not yet recruiting
1/2
10
RoW
QPOP, CURATE.AI, Azacitidine + docetaxel, Azacitidine + paclitaxel, Azacitidine + irinotecan
National University Hospital, Singapore, The N.1 Institute for Health (N.1), Cancer Science Institute of Singapore
Solid Tumor, Gastrointestinal Cancer, Breast Cancer
10/26
04/27
NCT05275777: A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Active, not recruiting
1/2
66
RoW
ADG106, Doxorubicin, Adriamycin, Cyclophosphamide, Cytophosphane, Paclitaxel, Taxol
National University Hospital, Singapore, Adagene Inc
HER2-negative Breast Cancer, Advanced Solid Tumor
12/27
02/30
ComPACT, NCT05491083: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Recruiting
1b
51
RoW
Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II)
National University Hospital, Singapore, Adagene Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Triple Negative Breast Cancer
12/25
12/26
QUEST, NCT05177432: Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer

Recruiting
1
26
RoW
QPOP
National University Hospital, Singapore
Breast Cancer
01/25
12/25
NCT04279509: Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE)

Recruiting
N/A
35
RoW
Tumor Core Biopsy, Blood sampling
National University Hospital, Singapore
Organoids, HNSCC, Epithelial Ovarian Cancer, Colorectal Cancer
05/21
05/22
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
NCT04915924: Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea

Completed
N/A
358
RoW
HeartMate 3™ left ventricular assist system (HM3 LVAS)
Abbott Medical Devices
Advanced Heart Failure
06/24
06/24
Lee, Sung Won
PEARLY, NCT02441933: Carboplatin in EARLY Triple Negative Breast Cancer Trial ( Trial)

Active, not recruiting
3
878
RoW
taxane plus carboplatin, Taxane
Yonsei University
Breast Cancer
06/25
06/25
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
SOLARIS, NCT04094688: Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer

Active, not recruiting
3
455
US
Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colorectal Adenocarcinoma
01/26
07/26
CASPAR, NCT04455750: A Clinical Study Evaluating the Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant to Testosterone-Deprivation Therapy

Active, not recruiting
3
61
US
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC V8, Stage IVA Prostate Cancer AJCC V8, Stage IVB Prostate Cancer AJCC V8
03/26
09/27
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting
3
150
Europe, Japan, US, RoW
Ianalumab, VAY736, Eltrombopag, ETB115, Placebo
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
08/25
05/28
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Recruiting
3
225
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo, Corticosteroids
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
04/26
12/28
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
TAILOR RT, NCT03488693: Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Recruiting
3
2140
Canada, US
Radiation, No Radiation
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
Breast Cancer
09/27
12/27
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
SWOG-S1501, NCT03418961: S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Recruiting
3
817
US, RoW
Carvedilol, Coreg, Laboratory Biomarker Analysis, Patient Observation, Active Surveillance, deferred therapy, expectant management, observation, Watchful Waiting
SWOG Cancer Research Network, National Cancer Institute (NCI)
Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
01/30
01/30
NCT04137107: Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients with Stage II-III Colorectal Cancer

Active, not recruiting
2/3
220
US, RoW
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Stage II Colorectal Cancer AJCC V8, Stage III Colorectal Cancer AJCC V8
02/26
12/26
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hourglass Nov 2024 - Dec 2024 : Initial data from trial in combination with Libtayo for advanced NSCLC
Recruiting
2/3
850
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals
Advanced Non-Small Cell Lung Cancer
03/30
02/32
NCT03382795: Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Active, not recruiting
2
63
RoW
EGFR
Korea University Guro Hospital, Chong Kun Dang Pharmaceutical Corp.
EGFR Positive Non-small Cell Lung Cancer
03/23
03/23
NCT06249854: Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2
70
RoW
Bojungikki-tang(BJIKT), Buzhong Yiqi Decoction, Hochu-ekki-to, Pembrolizumab
Korea Institute of Oriental Medicine
Non-small Cell Lung Cancer
12/25
12/25
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Recruiting
2
77
RoW
Lazertinib, LECLAZA
Sung Yong Lee, Yuhan Corporation
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
03/26
03/26
NCT05841472: Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting
2
60
RoW
Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
CrystalGenomics, Inc.
Non Squamous Non Small Cell Lung Cancer
08/26
12/26
NCT03932604: Atrial Sensing Capability for Better Detection of Atrial Fibrillation

Recruiting
N/A
640
RoW
Atrial sensing On mode
Samsung Medical Center, Biotronik SE & Co. KG
Implantable Cardioverter Defibrillator, Atrial Fibrillation, Cardiac Event, Cardiac Arrhythmia
12/21
05/23
PIVoTAL-IDE, NCT04505163: Left Atrial Posterior Wall and PV Isolation Using Cryoballoon for Treatment of Persistent AF

Active, not recruiting
N/A
153
US
Standard Cryoballoon Pulmonary Vein Isolation (PVI), Arctic Front Advance Cardiac Cryoablation System, Cryoballoon PVI + Posterior Wall Isolation
Dignity Health Medical Foundation, Mercy General Hospital and Dignity Health Medical Foundation, Beth Israel Deaconess Medical Center, UC Health Medical Center, MedStar Georgetown University Hospital and Medical Center, Tampa Cardiac Specialists, Bethesda North Hospital, Brigham and Women's Hospital, Texas Cardiac Arrhythmia Institute At St. Davids Medical Center, St. Luke's Hospital and Health Network, Pennsylvania, Sarasota Memorial Health Care System, Nebraska Methodist Hospital-Methodist Physicians Clinic
Persistent Atrial Fibrillation
04/24
12/24
KOBIO, NCT01965132: Korean College of Rheumatology Biologics and Targeted Therapy Registry

Recruiting
N/A
10000
RoW
Biologic or targeted synthetic DMARD, etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biosimilars, tofacitinib, baricitinib, upadacitinib
Seoul National University Hospital
Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
12/29
06/30
ALCHEMIST Screening, NCT02194738: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The Trial)

Recruiting
N/A
8300
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Echocardiography, EC, Erlotinib, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
09/26
09/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Kim, Hee Cheol
ROSUZET-AMI, NCT04499859: Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

Recruiting
4
3548
RoW
Ezetimibe 10mg + Rosuvastatin 5mg, Rosuzet 10/5 mg, Rosuvastatin 20mg, Crestor 20mg
Kiyuk Chang, MD,PhD
Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
08/26
08/27
PEARLY, NCT02441933: Carboplatin in EARLY Triple Negative Breast Cancer Trial ( Trial)

Active, not recruiting
3
878
RoW
taxane plus carboplatin, Taxane
Yonsei University
Breast Cancer
06/25
06/25
SELENIUM, NCT04201561: High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy

Active, not recruiting
3
68
RoW
sodium selenite pentahydrate, Selentab inj. A12CE02, Normal saline, sodium chloride 0.9%, Chemotherapy, Paclitaxel, carboplatin and bevacizumab
Seoul National University Hospital, Boryung Pharmaceutical Co., Ltd
Chemotherapy-induced Peripheral Neuropathy, Recurrent Ovarian Carcinoma, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
04/23
12/24
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
ROCOCO, NCT03693248: Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer

Recruiting
3
298
RoW
Two cycles of neoadjuvant chemotherapy, paclitaxel and carboplatin
Seoul National University Hospital
Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV, Fallopian Tube Cancer, Peritoneal Cancer
12/23
12/23
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Active, not recruiting
2/3
301
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen, Horizon Therapeutics USA, Inc
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
09/25
09/25
NCT04594694 / 2018-002575-17: Study of OCA in Combination with BZF Evaluating Efficacy, Safety, and Tolerability in Participants with PBC

Active, not recruiting
2
72
Europe, RoW
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate
Intercept Pharmaceuticals
Primary Biliary Cholangitis
10/25
10/25
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
NCT05626751 / 2021-006271-42: An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Enrolling by invitation
2
240
Europe, Japan, US, RoW
HZN-825
Amgen, Horizon Therapeutics USA, Inc, Horizon Therapeuthics USA, Inc
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
09/26
09/26
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
02/29
SOLUTION, NCT04370496: Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients

Recruiting
2
124
RoW
Minimally invasive surgery using endoscopic stapler
Seoul National University Hospital, Johnson & Johnson
Cervical Cancer, Cervical Cancer Stage IB1, Minimally Invasive Surgery
12/28
12/28
CREATIVE, NCT04678102: Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr ( Phase IA Trial)

Recruiting
1
36
RoW
PHI-101 administration, PHI-101
Seoul National University Hospital, Pharos iBio Co., Ltd.
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
12/23
12/23
NCT06800131: Hepatitis B Vaccine Delivered Trans-dermally by MAP

Not yet recruiting
1
40
NA
Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP), Active comparator vaccine via intramuscular injection
International Vaccine Institute, QuadMedicine
Hepatitis B Vaccine
08/26
11/26
NCT05972642: Safety & Efficacy of Non-Invasive Procedures Using Ultrasound-Guided HIFU 'Sonotrip V20' in Symptomatic Uterine Fibroids

Not yet recruiting
1
30
NA
HIFU-treatment, Treatment arm
Seoul National University Hospital, Jeysis Medical
Myoma;Uterus
08/25
12/25
SDLNOC, NCT05005650: Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy

Completed
N/A
121
RoW
debulking surgery
Seoul National University Hospital
Ovarian Cancer Stage IV, Lymph Node Metastases
08/21
12/21
VALENTINE, NCT04874246: Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy

Completed
N/A
39
RoW
Vasopressin, Vasopressin 20U
Seoul National University Hospital, CHA University
Uterine Leiomyoma
12/21
12/22
NCT05300828: Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer

Completed
N/A
600
RoW
Genexl PM
Seoul National University Hospital, Samyang Biopharmaceuticals Corporation
Ovarian Cancer
04/22
12/22
NCT04943263: A Comparison of Temperature Measurement During Living Donor Liver Transplantation

Not yet recruiting
N/A
22
RoW
Tracheal Temperature
Seoul National University Hospital, Oneclickmedical Co., Ltd. (Seoul, South Korea)
Living Donor Liver Transplantation
06/22
06/22
NCT04991220: Evaluation of the Changes of Pleth Variability Index During Preoxygenation for Predicting Hypotension

Not yet recruiting
N/A
96
RoW
Preoxygenation
Seoul National University Hospital, GEMSKOREA
Hypotension on Induction
08/22
12/22
NCT06084039: Reducing the Carbon Footprint Through Education on the Effects of Inhalation Anesthetics on Global Warming

Completed
N/A
4478
RoW
Pusan National University Yangsan Hospital
Anesthesia
02/23
09/23
NCT06656689: Study on Water Vapor Thermal Therapy

Recruiting
N/A
300
RoW
Rezum (water vapor thermal therapy)
Saint Vincent's Hospital, Korea
Benign Prostatic Hyperplasia
07/28
10/28
NCT06218745: Prediction Model for Postoperative AKI in Patients Undergoing Lung Transplantation Using Machine Learning

Recruiting
N/A
214
RoW
General anesthesia
Pusan National University Yangsan Hospital
Lung Transplantation
12/24
12/24
NCT06218758: Prediction Model for PPCs in Patients Undergoing Lung Transplantation Using Machine Learning

Recruiting
N/A
214
RoW
General anesthesia
Pusan National University Yangsan Hospital
Lung Transplantation
12/24
12/24
NCT06029283: Dietary Nitrate Functional Gum Effect on Gingivitis and Heart Health

Active, not recruiting
N/A
30
US
dietary nitrate, Placebo chewing gum
University of Maryland, Baltimore
Gingivitis, Cardiovascular Diseases, Gingival Diseases, Gingival Bleeding, Periodontal Diseases
08/25
08/25
NCT06385002: Effect of Combined Administration of Sevoflurane and Remimazolam on Emergence

Recruiting
N/A
24
RoW
Remimazolam, Byfavo
Pusan National University Yangsan Hospital
Gynecological Surgery
05/25
05/25
NCT05864625: Comparison of Hemodynamic Stability During Anesthesia Using Remimazolam and Sevoflurane in Minimally Invasive AVR

Recruiting
N/A
52
RoW
Remimazolam besylate, Remimazolam besylate, Byfavo Inj., Hana Pharm Col, Ltd., Seoul, Korea, Propofol/ Sevoflurane, Fresofol 1% TM, Fresenius
Pusan National University Yangsan Hospital
Aortic Valve Stenosis, Remimazolam
06/25
06/25
NCT05907525: Effect of Sevoflurane and Remimazolam on Arterial Oxygenation During One-lung Ventilation

Completed
N/A
66
RoW
Remimazolam, Byfavo, 1% propofol, Fresofol MCT 1%
Pusan National University Yangsan Hospital
One-Lung Ventilation, Thoracic Surgery, Video-Assisted, Remimazolam
04/24
04/24
NCT06053489: Effect of Remimazolam and Sevoflurane Anesthesia on Recovery in Pediatric Patients

Completed
N/A
146
RoW
general anesthesia with remimazolam
Pusan National University Yangsan Hospital
Ophthalmic Abnormalities, Pediatric Disorder
08/24
08/24
WARM-PA, NCT06041685: Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia

Recruiting
N/A
126
RoW
local warming
Pusan National University Yangsan Hospital
Congenital Heart Disease
12/25
12/25
REBOA, NCT06031623: in Nontraumatic OHCA

Recruiting
N/A
234
RoW
REBOA
Seoul National University Hospital, Far Eastern Memorial Hospital
Cardiopulmonary Arrest
10/25
10/26
FUSION IV, NCT02986568: Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers

Recruiting
N/A
380
RoW
Cervical cancer, Uterine cancer, Cervical cancer, pelvic sidewall invasion, Non-cervical cancer, pelvic sidewall invasion
Seoul National University Hospital
Cervical Cancer, Uterine Cancer
12/25
12/25
PRAHA-2, NCT04643106: Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function

Recruiting
N/A
90
RoW
Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy, suturing with barbed sutures during laparoscopic ovarian cystectomy
Seoul National University Hospital
Benign Ovarian Cyst
12/25
12/26
LAPSODY, NCT05431530: Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer

Recruiting
N/A
108
RoW
Cytoreductive surgery
Seoul National University Hospital
Ovarian Cancer, Low Anterior Resection Syndrome, Quality of Life
05/27
05/27
Prajapati, Vimal
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
05/25
09/25
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
310
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
Contact, Site Public
NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed
4
50
RoW
ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Hemophilia A
02/23
02/23
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Completed
4
4
US
Digital Engagement Application (GD App), No Intervention
Takeda
Gaucher Disease
02/23
02/23
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting
4
80
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
05/25
05/25
TAK-665-4001, NCT05058391 / 2022-004193-39: A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed
4
5
RoW
Elaprase, Idursulfase
Takeda, Takeda Biopharmaceuticals India Pvt. Ltd.
Hunter Syndrome
04/24
04/24
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Completed
4
10
RoW
Brentuximab vedotin, SGN-35
Takeda
T-Cell Lymphoma
08/24
08/24
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India

Active, not recruiting
4
5
RoW
Replagal
Shire
Fabry Disease
10/26
11/26
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Active, not recruiting
4
50
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
03/26
03/26
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting
4
5
US
ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Takeda, Takeda Development Center Americas, Inc.
Mucopolysaccharidosis (MPS), Hunter Syndrome
07/28
07/28
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT03927027: Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Active, not recruiting
3
534
US
Isosulfan Blue, Axillary Lymph Node Dissection, ALND, axillary dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
11/26
01/27
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
51
Europe, Japan, US
BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
SWOG-S1600, NCT03757949: Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

Active, not recruiting
3
203
US
Laboratory Biomarker Analysis, Nutritional Intervention, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Bladder Carcinoma
01/24
01/27
NCT03550391: Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting
3
206
Canada, US
Memantine, Hippocampal-avoidant (HA-WBRT) Radiotherapy, Stereotactic Radiosurgery (SRS)
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, NRG Oncology
Brain Metastases
06/27
12/27
 

Download Options